Seek Returns logo

DIS vs. NVO: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at DIS and NVO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

DIS is a standard domestic listing, while NVO trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.

SymbolDISNVO
Company NameThe Walt Disney CompanyNovo Nordisk A/S
CountryUnited StatesDenmark
GICS SectorCommunication ServicesHealth Care
GICS IndustryEntertainmentPharmaceuticals
Market Capitalization210.43 billion USD240.04 billion USD
ExchangeNYSENYSE
Listing DateJanuary 2, 1962April 30, 1981
Security TypeCommon StockADR

Historical Performance

This chart compares the performance of DIS and NVO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

DIS vs. NVO: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolDISNVO
5-Day Price Return0.63%6.80%
13-Week Price Return3.89%-19.59%
26-Week Price Return6.80%-44.66%
52-Week Price Return28.87%67.26%
Month-to-Date Return-1.74%10.67%
Year-to-Date Return5.11%-44.24%
10-Day Avg. Volume8.21M10.57M
3-Month Avg. Volume9.68M6.69M
3-Month Volatility18.15%64.82%
Beta1.571.51

Profitability

Return on Equity (TTM)

DIS

11.10%

Entertainment Industry

Max
42.50%
Q3
22.75%
Median
12.88%
Q1
7.15%
Min
-6.84%

DIS’s Return on Equity of 11.10% is on par with the norm for the Entertainment industry, indicating its profitability relative to shareholder equity is typical for the sector.

NVO

77.86%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

DIS vs. NVO: A comparison of their Return on Equity (TTM) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

DIS

12.22%

Entertainment Industry

Max
45.25%
Q3
23.93%
Median
14.60%
Q1
4.89%
Min
-22.94%

DIS’s Net Profit Margin of 12.22% is aligned with the median group of its peers in the Entertainment industry. This indicates its ability to convert revenue into profit is typical for the sector.

NVO

35.61%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

NVO’s Net Profit Margin of 35.61% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.

DIS vs. NVO: A comparison of their Net Profit Margin (TTM) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

DIS

12.69%

Entertainment Industry

Max
46.83%
Q3
28.87%
Median
15.26%
Q1
8.95%
Min
-5.53%

DIS’s Operating Profit Margin of 12.69% is around the midpoint for the Entertainment industry, indicating that its efficiency in managing core business operations is typical for the sector.

NVO

45.78%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

NVO’s Operating Profit Margin of 45.78% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.

DIS vs. NVO: A comparison of their Operating Profit Margin (TTM) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolDISNVO
Return on Equity (TTM)11.10%77.86%
Return on Assets (TTM)5.88%24.22%
Net Profit Margin (TTM)12.22%35.61%
Operating Profit Margin (TTM)12.69%45.78%
Gross Profit Margin (TTM)37.61%83.95%

Financial Strength

Current Ratio (MRQ)

DIS

0.72

Entertainment Industry

Max
6.80
Q3
3.77
Median
1.87
Q1
0.86
Min
0.39

DIS’s Current Ratio of 0.72 falls into the lower quartile for the Entertainment industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

NVO

0.78

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

DIS vs. NVO: A comparison of their Current Ratio (MRQ) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

DIS

0.39

Entertainment Industry

Max
1.65
Q3
0.71
Median
0.14
Q1
0.04
Min
0.00

DIS’s Debt-to-Equity Ratio of 0.39 is typical for the Entertainment industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

NVO

0.59

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

DIS vs. NVO: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

DIS

7.95

Entertainment Industry

Max
62.11
Q3
31.19
Median
7.50
Q1
2.02
Min
-6.33

DIS’s Interest Coverage Ratio of 7.95 is positioned comfortably within the norm for the Entertainment industry, indicating a standard and healthy capacity to cover its interest payments.

NVO

149.07

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.

DIS vs. NVO: A comparison of their Interest Coverage Ratio (TTM) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolDISNVO
Current Ratio (MRQ)0.720.78
Quick Ratio (MRQ)0.660.56
Debt-to-Equity Ratio (MRQ)0.390.59
Interest Coverage Ratio (TTM)7.95149.07

Growth

Revenue Growth

DIS vs. NVO: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

DIS vs. NVO: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

DIS

0.82%

Entertainment Industry

Max
2.54%
Q3
1.29%
Median
0.61%
Q1
0.00%
Min
0.00%

DIS’s Dividend Yield of 0.82% is consistent with its peers in the Entertainment industry, providing a dividend return that is standard for its sector.

NVO

3.30%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

NVO’s Dividend Yield of 3.30% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

DIS vs. NVO: A comparison of their Dividend Yield (TTM) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

DIS

46.10%

Entertainment Industry

Max
82.30%
Q3
45.76%
Median
29.16%
Q1
0.00%
Min
0.00%

DIS’s Dividend Payout Ratio of 46.10% is in the upper quartile for the Entertainment industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

NVO

61.60%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

DIS vs. NVO: A comparison of their Dividend Payout Ratio (TTM) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolDISNVO
Dividend Yield (TTM)0.82%3.30%
Dividend Payout Ratio (TTM)46.10%61.60%

Valuation

Price-to-Earnings Ratio (TTM)

DIS

18.15

Entertainment Industry

Max
53.51
Q3
45.31
Median
33.16
Q1
18.21
Min
3.89

In the lower quartile for the Entertainment industry, DIS’s P/E Ratio of 18.15 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

NVO

13.91

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.91 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

DIS vs. NVO: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

DIS

2.22

Entertainment Industry

Max
12.81
Q3
7.20
Median
4.68
Q1
3.32
Min
0.79

In the lower quartile for the Entertainment industry, DIS’s P/S Ratio of 2.22 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

NVO

4.95

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

NVO’s P/S Ratio of 4.95 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

DIS vs. NVO: A comparison of their Price-to-Sales Ratio (TTM) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

DIS

2.04

Entertainment Industry

Max
17.11
Q3
8.38
Median
5.24
Q1
2.18
Min
0.67

DIS’s P/B Ratio of 2.04 is in the lower quartile for the Entertainment industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

NVO

8.87

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

DIS vs. NVO: A comparison of their Price-to-Book Ratio (MRQ) against their respective Entertainment and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolDISNVO
Price-to-Earnings Ratio (TTM)18.1513.91
Price-to-Sales Ratio (TTM)2.224.95
Price-to-Book Ratio (MRQ)2.048.87
Price-to-Free Cash Flow Ratio (TTM)18.1623.46